BioNTech Results Presentation Deck

Potential to Tackle Multiple Diseases with Different Therapeutic Modalities Next Generation Immunomodulators mRNA Cancer Vaccines iNeST Fix Vac • Multi-specificity, multi-valency, high (neo)antigen specific T cell responses with unprecedented potency 3 Phase 2 randomized trials (iNeST and 2 FixVac) Next Gen CAR-T Cell / Neoantigen-based T Cell Therapy Phase 1 FIH trials started in Feb. and Apr 2021 20 Cell Therapies Targeting Cancer Targeted Cancer Antibodies CA 19-9 antibody in 1L pancreatic cancer Phase 1/2 trial Antibodies · ● Immunomodulatio ● ● TLR-7 Agonist Potently modulates innate immunity Potential for combination with other 10 agents Phase 1 trial Small Molecule Immunomodulators ● Bispecifics Next-generation checkpoint inhibitors to address a broad range of cancers Phase 1/2 trials of 2 bi-specific antibodies Ribocytokines mRNA encoded cytokines with a prolonged T1/2 and improved safety profile ● ● H Potential to amplify vaccines and CPIs Phase 1 FIH trials started in Feb. and Jun. 2021 Engineered Biologicals Oncology: Multiple product opportunities with unique combination potential in clinical testing CAR, Chimeric antigen receptor; CA 19-9: Cancer antigen 19-9; 10, Immuno-oncology; CPI, Check-point Inhibitor; FIH, First-in-human; TLR-7, Toll-like receptor 7; T1/2, half-life BIONTECH

View entire presentation